Nutex Health Inc. (NUTX): Results of Operations and Financial Condition
Nutex Health Inc. (NUTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS HOUSTON, TX − (PRNewswire) – AUGUST 6, 2026 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six months ended June 30, 2026. Nutex Health is a physi
How this was made
The 30-second read
Why it matters
Traders should focus on the magnitude of the profitability and cash-flow improvement versus the concurrent revenue decline, and on the disclosed cost drivers from the HaloMD agreement amendment and CMS administrative fee reduction, which management expects to lower normalized contract services expenses prospectively.
Market read
A quantified earnings and operating update with a specific, disclosed mechanism for lower contract services expenses and a forward-looking estimate of normalized cost reduction.
What to watch
The revenue decline is attributed to early-stage IDR process results realized in 1H 2025, and the normalized contract services expense reduction is expectation-based and could diverge from actual future costs.
Nutex Health reported second-quarter net income attributable to Nutex Health Inc. of $65.8 million, or diluted EPS of $9.38, as total revenue decreased 13.6% to $210.8 million.
Profitability and operating cash flow improved sharply, supported by a $52.3 million reduction in contract services expense and lower stock-based compensation, while total revenue and same-hospital revenue declined and accounts receivable increased.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $ 210,752 (In thousands) | – | decreased 13.6% |
| Hospital division revenueGAAP | $ 201,852 (In thousands) | – | – |
| Population health management division revenueGAAP | $ 8,900 (In thousands) | – | – |
| PayrollGAAP | $ 42,751 (In thousands) | – | – |
| Contract servicesGAAP | $ 1,082 (In thousands) | – | – |
| Medical suppliesGAAP | $ 5,342 (In thousands) | – | – |
| Depreciation and amortizationGAAP | $ 5,317 (In thousands) | – | – |
| Other operating costs and expensesGAAP | $ 14,981 (In thousands) | – | – |
| Total operating costs and expensesGAAP | $ 69,473 (In thousands) | – | – |
| Gross profitGAAP | $ 141,279 (In thousands) | – | – |
| Stock-based compensationGAAP | $ 2,884 (In thousands) | – | – |
| General and administrative expensesGAAP | $ 16,677 (In thousands) | – | – |
| Total corporate and other costsGAAP | $ 19,561 (In thousands) | – | – |
| Operating incomeGAAP | $ 121,718 (In thousands) | – | – |
| Interest expense, netGAAP | $ 4,671 (In thousands) | – | – |
| Other expenseGAAP | $ 38 (In thousands) | – | – |
| Income before taxesGAAP | $ 117,085 (In thousands) | – | – |
| Income tax expenseGAAP | $ 20,768 (In thousands) | – | – |
| Net incomeGAAP | $ 96,317 (In thousands) | – | – |
| Net income attributable to Nutex Health Inc.GAAP | $ 65,842 (In thousands) | – | increased to $65.8 million from a loss of $17.7 million |
| Basic earnings per common shareGAAP | $ 9.58 | – | – |
| Diluted earnings per common shareGAAP | $ 9.38 | – | increased to $9.38 from $(2.95) |
| EBITDA attributable to Nutex Healthnon-GAAP | $ 94,146 (In thousands) | – | – |
| Adjusted EBITDA attributable to Nutex Healthnon-GAAP | $ 89,985 (In thousands) | – | – |
| Net cash provided by operating activitiesGAAP | $34.2 million | – | – |
| Total revenue, six months ended June 30GAAP | $ 427,237 (In thousands) | – | decreased 6.3% |
| Operating income, six months ended June 30GAAP | $ 202,983 (In thousands) | – | – |
| Net income attributable to Nutex Health Inc., six months ended June 30GAAP | $ 112,649 (In thousands) | – | increased 3100% |
| Diluted earnings per common share, six months ended June 30GAAP | $ 15.87 | – | – |
| EBITDA attributable to Nutex Health, six months ended June 30non-GAAP | $ 162,451 (In thousands) | – | – |
| Adjusted EBITDA attributable to Nutex Health, six months ended June 30non-GAAP | $ 147,549 (In thousands) | – | – |
| Net cash provided by operating activities, six months ended June 30GAAP | $ 109,718 (In thousands) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Hospital divisionTotal visits at the Hospital Division increased 9.6% year over year to 49,962, while visits at same hospitals increased 6.3%. | $ 201,852 (In thousands) | – | – |
| Population health management divisionNot specified in the filing. | $ 8,900 (In thousands) | – | – |
Prospectively outlook
- NoteBased on current expectations, we anticipate the impact of these favorable changes will lead to an approximate 25-30% reduction in our normalized historical contract services expenses prospectively.
- NoteExpected opening of three new hospital later this year.
Capital returns
- Cash related to stock repurchases and retirements of $ 50,688 (In thousands) for the six months ended June 30, 2026.
- Members' distributions of $ 28,620 (In thousands) for the six months ended June 30, 2026.
What drove it
- Total visits at the Hospital Division increased 9.6% year over year to 49,962, while visits at same hospitals increased 6.3%.
- The Company stated that most of the 2026 revenue decrease compared to 2025 was due to the positive results from the early stage improvement in the IDR process that were realized in the first half of 2025.
- Total arbitration-related costs decreased, reflected as a $52.3 million reduction to contract services expense.
- The contract services reduction was driven primarily by the favorable June 30, 2026 retroactive amendment to the HaloMD agreement and the reduction in the CMS administrative fee.
- The CMS administrative fee for the federal IDR process was decreased from $115 to $15 per party per dispute effective June 11, 2026.
- Total stock-based compensation for the six months ended June 30, 2026 was a gain of $1.0 million, compared to an expense of $106.4 million for the same period in 2025.
Concerns
- Total revenue decreased 13.6% to $210.8 million for the three months ended June 30, 2026, while revenue at same hospitals decreased 12.1%.
- Accounts receivable increased to $ 351,675 (In thousands) as of June 30, 2026 from $ 319,440 (In thousands) as of December 31, 2025.
- Actual contract services expenses incurred in the future may differ significantly from the Company's current expectations.
- The filing identifies regulatory and litigation uncertainty under the No Surprises Act and lawsuits filed by health insurance providers against the Company's third party provider in the arbitration process.
What to watch
- Whether the anticipated approximate 25-30% reduction in normalized historical contract services expenses is realized prospectively.
- IDR execution, including the Company’s statement that it has submitted between 50–60% of its claims through IDR, prevails in over 85% of award determinations, and collects on average over 80% of award amounts.
- Revenue and same-hospital revenue trends following the second-quarter declines.
- The expected opening of three new hospital later this year.
- Accounts receivable and operating cash flow conversion.
Balance sheet and cash flow
- Cash and cash equivalents of $ 205,208 (In thousands) as of June 30, 2026, compared to $ 185,574 (In thousands) as of December 31, 2025.
- Restricted cash of $ 1,900 (In thousands) as of June 30, 2026, compared to $ 297 (In thousands) as of December 31, 2025.
- Accounts receivable of $ 351,675 (In thousands) as of June 30, 2026, compared to $ 319,440 (In thousands) as of December 31, 2025.
- Total assets of $ 964,629 (In thousands) as of June 30, 2026, compared to $ 918,525 (In thousands) as of December 31, 2025.
- Lines of credit of $ 98 (In thousands) as of June 30, 2026, compared to $ 740 (In thousands) as of December 31, 2025.
- Current portion of long-term debt of $ 8,496 (In thousands) as of June 30, 2026, compared to $ 13,336 (In thousands) as of December 31, 2025.
- Long-term debt, net of $ 31,105 (In thousands) as of June 30, 2026, compared to $ 29,174 (In thousands) as of December 31, 2025.
- Financing lease liabilities, current portion of $ 7,271 (In thousands) and non-current financing lease liabilities, net of $ 268,905 (In thousands) as of June 30, 2026.
- Total liabilities of $ 457,317 (In thousands) as of June 30, 2026, compared to $ 495,088 (In thousands) as of December 31, 2025.
- Nutex Health Inc. equity of $ 394,316 (In thousands) as of June 30, 2026, compared to $ 329,447 (In thousands) as of December 31, 2025.
- Net cash provided by operating activities of $ 109,718 (In thousands) for the six months ended June 30, 2026, compared to $ 78,222 (In thousands) for the six months ended June 30, 2025.
- Acquisitions of property and equipment of $ 3,741 (In thousands) for the six months ended June 30, 2026, compared to $ 815 (In thousands) for the six months ended June 30, 2025.
- Net cash used in financing activities of $ 84,740 (In thousands) for the six months ended June 30, 2026, compared to $ 22,261 (In thousands) for the six months ended June 30, 2025.
- Net change in cash, cash equivalents, and restricted cash of $ 21,237 (In thousands) for the six months ended June 30, 2026, compared to $ 56,093 (In thousands) for the six months ended June 30, 2025.
- Cash and cash equivalents and restricted cash - end of period of $ 207,108 (In thousands) for the six months ended June 30, 2026, compared to $ 96,733 (In thousands) for the six months ended June 30, 2025.
Analysis
Nutex Health’s second-quarter results showed a pronounced split between revenue and profitability. Total revenue decreased 13.6% to $210.8 million, and same-hospital revenue decreased 12.1%, despite Hospital Division visits increasing 9.6% to 49,962 and same-hospital visits increasing 6.3%. The Company attributed most of the 2026 revenue decrease versus 2025 to positive results from early-stage IDR process improvement that were realized in the first half of 2025. Population Health Management Division revenue was $8.9 million, compared with $7.7 million in the prior-year quarter.
The earnings improvement was driven by expenses rather than revenue. Contract services expense was $1.1 million, compared with $61.1 million in the prior-year quarter, while total operating costs and expenses were $69.5 million versus $119.1 million. The Company identified a $52.3 million reduction in contract services expense from a retroactive HaloMD agreement amendment and the reduction in the CMS administrative fee. Stock-based compensation was also $2.9 million in the quarter, compared with $78.7 million a year earlier. These cost changes lifted operating income to $121.7 million from $33.7 million and net income attributable to Nutex Health Inc. to $65.8 million from a loss of $17.7 million.
Cash generation was positive. Net cash provided by operating activities was $34.2 million in the quarter, compared with $27.3 million in the prior-year period, and was $109.7 million for the first six months of 2026. Cash and cash equivalents were $205.2 million at June 30, 2026, while long-term debt, net was $31.1 million. The Company used $50.7 million for stock repurchases and retirements during the first six months. Accounts receivable increased to $351.7 million from $319.4 million at December 31, 2025, making cash conversion and collections an important area of focus.
Management’s forward commentary centers on prospective contract services savings and hospital expansion. The Company expects the favorable HaloMD and CMS changes to produce an approximate 25-30% reduction in normalized historical contract services expenses prospectively, while cautioning that actual future expenses may differ significantly. It also expects to open three new hospital later this year. The key reported operating tension remains rising patient visits alongside declining revenue, with the durability of IDR collections, the prospective expense structure, and same-hospital revenue trends determining whether the current profitability level can be sustained.
Management, verbatim
2026 is continuing to be a solid financial year, including total revenue of $427.2 million, net income attributable to Nutex of $112.6 million, diluted EPS of $15.87 per share and $109.7 million of operating cash flow in the first six months of 2026. We also delivered meaningful operating income improvement, with operating income increasing to $203.0 million for the first six months of 2026 from $114.3 million in the same period of 2025, supported by lower total operating costs and expenses of $194.2 million compared to $212.5 million in the prior-year period. Our balance sheet remains strong with a cash balance of $205.2 million and long-term debt of $31.1 million. We believe we are set up well for finishing the year strong as we continue to grow with the expected opening of three new hospital later this year,
Jon Bates, Chief Financial Officer of Nutex Health
We are pleased with our progress through the first half of 2026, as our teams continue to execute on initiatives designed to strengthen internal processes and initiatives, expand patient access, and drive both patient volumes and inpatient admissions. Our operating performance, revenue cycle management execution, new hospital openings and disciplined expense management all contributed to improved profitability, including net income attributable to Nutex Health of $112.6 million and diluted EPS of $15.87 for the first six months of 2026,
Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health
Not in the filing
stated, not guessed- GAAP gross margin
- non-GAAP EPS
- free cash flow
- quarterly cash flow statement detail
- formal revenue guidance
- formal gross margin guidance
- formal operating expense guidance
- formal tax rate guidance
- prior-quarter comparisons for reported financial metrics
- dividend information
- segment revenue percentage changes
- full balance-sheet and cash-flow line-item presentation in the structured fields
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The 8-K (Item 2.02) includes an EX-99.1 earnings release for Nutex Health’s second quarter and first half of 2026, with non-GAAP metrics and operational KPIs (visits) plus reimbursement/IDR process commentary.
Ticker impact
Nutex Health reported Q2 and six-month 2026 results in an 8-K, including net income, EBITDA, visit growth, and operating cash flow.
Near-term bias to the upside on profitability and cash-flow improvement, tempered by the reported revenue decline and reliance on favorable IDR and contract-cost changes.
This is a primary earnings-style disclosure with multiple quantified KPIs (net income, EPS, operating cash flow, visits) plus a specific cost driver (HaloMD retroactive amendment and CMS fee reduction) and a forward-looking normalized contract services expense reduction estimate.
Market effects
Highlights how IDR process outcomes and administrative fee structures can materially affect healthcare services operators’ cost base and normalized expenses.
No specific regional market impact beyond the company’s multi-state hospital footprint.
Primarily US healthcare services and reimbursement-process dynamics; limited global spillover.
Counterpoint
Revenue is down year over year in both the quarter and six-month period, so the earnings rebound may be more cost-timing and process-driven than demand-driven.
Key entities
- public_companyNutex Health Inc.
Physician-led healthcare services and operations company with hospital facilities and a primary care-centric risk-bearing physician network.
- counterpartyHaloMD
Agreement counterparty whose June 30, 2026 retroactive amendment shifted certain fees to pay-on-collected basis and revised service fee terms.
- regulatorCMS (Centers for Medicare & Medicaid Services)
Administrative fee for the federal IDR process was reduced from $115 to $15 per party per dispute effective June 11, 2026.
